JP2004511208A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2004511208A5 JP2004511208A5 JP2001580948A JP2001580948A JP2004511208A5 JP 2004511208 A5 JP2004511208 A5 JP 2004511208A5 JP 2001580948 A JP2001580948 A JP 2001580948A JP 2001580948 A JP2001580948 A JP 2001580948A JP 2004511208 A5 JP2004511208 A5 JP 2004511208A5
- Authority
- JP
- Japan
- Prior art keywords
- polynucleotide
- seq
- polypeptide
- amino acid
- acid sequence
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 229920000023 polynucleotide Polymers 0.000 claims 139
- 239000002157 polynucleotide Substances 0.000 claims 139
- 229920001184 polypeptide Polymers 0.000 claims 93
- 125000003275 alpha amino acid group Chemical group 0.000 claims 60
- 108090001123 antibodies Proteins 0.000 claims 28
- 102000004965 antibodies Human genes 0.000 claims 28
- 150000001875 compounds Chemical class 0.000 claims 25
- 239000000523 sample Substances 0.000 claims 21
- 230000014509 gene expression Effects 0.000 claims 12
- 230000000694 effects Effects 0.000 claims 9
- 239000012472 biological sample Substances 0.000 claims 8
- 238000009396 hybridization Methods 0.000 claims 8
- 201000010099 disease Diseases 0.000 claims 6
- 238000004519 manufacturing process Methods 0.000 claims 5
- 210000004027 cells Anatomy 0.000 claims 4
- 108010045030 monoclonal antibodies Proteins 0.000 claims 4
- 102000005614 monoclonal antibodies Human genes 0.000 claims 4
- 239000002773 nucleotide Substances 0.000 claims 4
- 125000003729 nucleotide group Chemical group 0.000 claims 4
- 239000000556 agonist Substances 0.000 claims 3
- 230000003042 antagnostic Effects 0.000 claims 3
- 239000005557 antagonist Substances 0.000 claims 3
- 230000000295 complement Effects 0.000 claims 3
- 230000002163 immunogen Effects 0.000 claims 3
- 239000000546 pharmaceutic aid Substances 0.000 claims 3
- 108091008117 polyclonal antibodies Proteins 0.000 claims 3
- 230000001988 toxicity Effects 0.000 claims 3
- 231100000419 toxicity Toxicity 0.000 claims 3
- 229920000160 (ribonucleotides)n+m Polymers 0.000 claims 2
- 230000035693 Fab Effects 0.000 claims 2
- 210000004408 Hybridomas Anatomy 0.000 claims 2
- 239000000969 carrier Substances 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 210000000628 Antibody-Producing Cells Anatomy 0.000 claims 1
- 102000018358 Immunoglobulins Human genes 0.000 claims 1
- 108060003951 Immunoglobulins Proteins 0.000 claims 1
- 150000001413 amino acids Chemical class 0.000 claims 1
- 230000003321 amplification Effects 0.000 claims 1
- 108091006028 chimera Proteins 0.000 claims 1
- 230000002596 correlated Effects 0.000 claims 1
- 230000003247 decreasing Effects 0.000 claims 1
- 238000001514 detection method Methods 0.000 claims 1
- 235000003869 genetically modified organisms (GMOs) Nutrition 0.000 claims 1
- 238000003199 nucleic acid amplification method Methods 0.000 claims 1
- 230000002018 overexpression Effects 0.000 claims 1
- 238000003752 polymerase chain reaction Methods 0.000 claims 1
- 102000004169 proteins and genes Human genes 0.000 claims 1
- 108090000623 proteins and genes Proteins 0.000 claims 1
Claims (138)
(a)SEQ ID NO:1乃至SEQ ID NO:47(SEQ ID NO:1−47)からなる群から選択されたアミノ酸を含むポリペプチドと、
(b)SEQ ID NO:1−47からなる群から選択されたアミノ酸配列と少なくとも90%の同一性を有するアミノ酸配列を含む天然のポリペプチドと、
(c)SEQ ID NO:1−47からなる群から選択されたアミノ酸配列を有するポリペプチドの生物学的に活性な断片と、
(d)SEQ ID NO:1−47からなる群から選択されたアミノ酸配列を有するポリペプチドの免疫原性断片とで構成される群から選択されることを特徴とする単離されたポリペプチド。An isolated polypeptide comprising:
(A) a polypeptide comprising an amino acid selected from the group consisting of SEQ ID NO: 1 to SEQ ID NO: 47 (SEQ ID NO: 1-47);
(B) a natural polypeptide comprising an amino acid sequence having at least 90% identity with an amino acid sequence selected from the group consisting of SEQ ID NO: 1-47;
(C) a biologically active fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1-47;
(D) An isolated polypeptide selected from the group consisting of an immunogenic fragment of a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1-47.
(a)前記ポリペプチドの発現に好適な条件下で、請求項1のポリペプチドをコードするポリヌクレオチドに機能的に結合されたプロモーター配列を含む組換えポリヌクレオチドで形質転換された細胞を培養するステップと、
(b)そのように発現したポリペプチドを回収するステップとを含むことを特徴とする請求項1のポリペプチドの生産方法。A method for producing the polypeptide of claim 1, comprising:
(A) culturing cells transformed with a recombinant polynucleotide comprising a promoter sequence operably linked to a polynucleotide encoding the polypeptide of claim 1 under conditions suitable for expression of said polypeptide. Steps,
And (b) recovering the polypeptide so expressed. 2. The method for producing a polypeptide according to claim 1,
(a)SEQ ID NO:48−94からなる群から選択されたポリヌクレオチド配列を含むポリヌクレオチドと、
(b)SEQ ID NO:48−94からなる群から選択されたポリヌクレオチド配列と少なくとも90%の同一性を有するポリヌクレオチド配列を含む天然のポリヌクレオチドと、
(c)前記(a)のポリヌクレオチドに相補的なポリヌクレオチドと、
(d)前記(b)のポリヌクレオチドに相補的なポリヌクレオチドと、
(e)前記(a)乃至(d)のRNA等価物とで構成される群から選択された単離されたポリヌクレオチド。An isolated polynucleotide comprising:
(A) a polynucleotide comprising a polynucleotide sequence selected from the group consisting of SEQ ID NO: 48-94;
(B) a natural polynucleotide comprising a polynucleotide sequence having at least 90% identity with a polynucleotide sequence selected from the group consisting of SEQ ID NO: 48-94;
(C) a polynucleotide complementary to the polynucleotide of (a),
(D) a polynucleotide complementary to the polynucleotide of (b),
(E) An isolated polynucleotide selected from the group consisting of the RNA equivalents of (a) to (d) above.
(a)前記サンプルをプローブでハイブリダイズするステップであって、前記プローブが、前記サンプル内の前記標的ポリヌクレオチドに相補的な配列を含む少なくとも20個の連続するヌクレオチドを含み、前記プローブと前記標的ポリヌクレオチドまたはその断片との間でハイブリダイゼーション複合体が形成される条件下で、前記プローブが前記標的ポリヌクレオチドに特異的にハイブリダイズする、該ステップと、
(b)前記ハイブリダイゼーション複合体が存在するか否かを検出し、存在する場合には必要に応じてその収量を測定するステップとを含むことを特徴とする標的ポリヌクレオチドの検出方法。A method for detecting a target polynucleotide having a polynucleotide sequence according to claim 11 in a sample comprising:
(A) hybridizing the sample with a probe, the probe comprising at least 20 consecutive nucleotides comprising a sequence complementary to the target polynucleotide in the sample, wherein the probe and the target The probe specifically hybridizes to the target polynucleotide under conditions that form a hybridization complex with the polynucleotide or fragment thereof;
(B) detecting whether or not the hybridization complex is present and, if present, measuring the yield as necessary, comprising a method for detecting a target polynucleotide.
(a)ポリメラーゼ連鎖反応増幅法を用いて、前記標的ポリヌクレオチドまたはその断片を増幅するステップと、
(b)増幅された前記標的ポリヌクレオチドまたはその断片が存在するか否かを検出し、存在する場合には必要に応じてその収量を測定するステップとを含むことを特徴とする標的ポリヌクレオチドの検出方法。A method for detecting a target polynucleotide having the polynucleotide sequence of claim 11 in a sample comprising:
(A) amplifying the target polynucleotide or fragment thereof using polymerase chain reaction amplification;
(B) detecting whether the amplified target polynucleotide or a fragment thereof is present and, if present, measuring the yield as necessary, Detection method.
(a)請求項1のポリペプチドを含むサンプルを化合物に曝露するステップと、
(b)前記サンプルにおいてアゴニスト活性を検出するステップとを含むことを特徴とするスクリーニング方法。A method of screening for compounds effective as agonists of the polypeptide of claim 1, comprising the steps of:
(A) exposing a sample comprising the polypeptide of claim 1 to a compound;
(B) detecting the agonist activity in the sample.
(a)請求項1のポリペプチドを含むサンプルを化合物に曝露するステップと、
(b)前記サンプルにおけるアンタゴニスト活性を検出するステップとを含むことを特徴とするスクリーニング方法。A method of screening for compounds effective as antagonists of the polypeptide of claim 1, comprising the steps of:
(A) exposing a sample comprising the polypeptide of claim 1 to a compound;
(B) detecting the antagonist activity in the sample.
(a)請求項1のポリペプチドを好適な条件下で少なくとも1つの試験化合物と結合させるステップと、
(b)請求項1のポリペプチドと前記試験化合物との結合を検出して、請求項1のポリペプチドと特異的に結合する化合物を同定するステップとを含むことを特徴とするスクリーニング方法。A method for screening for a compound that specifically binds to the polypeptide of claim 1 comprising:
(A) binding the polypeptide of claim 1 to at least one test compound under suitable conditions;
(B) detecting the binding between the polypeptide of claim 1 and the test compound, and identifying a compound that specifically binds to the polypeptide of claim 1.
(a)請求項1のポリペプチドを、そのポリペプチドの活性が許容される条件下で少なくとも1つの試験化合物と結合させるステップと、
(b)前記試験化合物の存在下での請求項1のポリペプチドの活性を評価するステップと、
(c)前記試験化合物の存在下での請求項1のポリペプチドの活性と、前記試験化合物の非存在下での請求項1のポリペプチドの活性とを比較するステップとを含み、
前記試験化合物の存在下での請求項1のポリペプチドの活性の変化が、請求項1のポリペプチドの活性を変化させる化合物の存在を示唆することを特徴とするスクリーニング方法。A method for screening for a compound that alters the activity of the polypeptide of claim 1 comprising:
(A) binding the polypeptide of claim 1 to at least one test compound under conditions that permit activity of the polypeptide;
(B) evaluating the activity of the polypeptide of claim 1 in the presence of said test compound;
(C) comparing the activity of the polypeptide of claim 1 in the presence of the test compound with the activity of the polypeptide of claim 1 in the absence of the test compound;
A screening method characterized in that a change in the activity of the polypeptide of claim 1 in the presence of the test compound suggests the presence of a compound that alters the activity of the polypeptide of claim 1.
(a)前記標的ポリヌクレオチドの発現に好適な条件下で、前記標的ポリヌクレオチドを含むサンプルを化合物に曝露するステップと、
(b)前記標的ポリヌクレオチドの発現の変化を検出するステップと、
(c)様々な量の前記化合物の存在下での前記標的ポリヌクレオチドの発現と、前記化合物の非存在下での前記標的ポリヌクレオチドの発現とを比較するステップとを含むことを特徴とするスクリーニング方法。A method of screening for compounds effective to alter the expression of a target polynucleotide comprising the sequence of claim 5 comprising:
(A) exposing a sample containing the target polynucleotide to a compound under conditions suitable for expression of the target polynucleotide;
(B) detecting a change in expression of the target polynucleotide;
(C) comparing the expression of the target polynucleotide in the presence of various amounts of the compound with the expression of the target polynucleotide in the absence of the compound. Method.
(a)核酸を含む生体サンプルを前記試験化合物で処理するステップと、
(b)処理した前記生体サンプルの核酸を、請求項11のポリヌクレオチドの少なくとも20個の連続するヌクレオチドを含むプローブとハイブリダイズさせるステップであって、このハイブリダイゼーションが、前記プローブと前記生体サンプルの標的ポリヌクレオチドとの間で特異的なハイブリダイゼーション複合体が形成される条件下で行われ、前記標的ポリヌクレオチドが、請求項11のポリヌクレオチドのポリヌクレオチド配列またはその断片を含むポリヌクレオチドである、前記ステップと、
(c)ハイブリダイゼーション複合体の収量を定量するステップと、
(d)前記処理した生体サンプルにおけるハイブリダイゼーション複合体の収量を、未処理の生体サンプルにおけるハイブリダイゼーション複合体の収量と比較するステップとを含み、
前記処理した生体サンプルにおけるハイブリダイゼーション複合体の収量の差が試験化合物の毒性を示唆することを特徴とする試験化合物の毒性評価方法。A method for assessing the toxicity of a test compound comprising:
(A) treating a biological sample containing nucleic acid with the test compound;
(B) hybridizing the treated nucleic acid of the biological sample with a probe comprising at least 20 contiguous nucleotides of the polynucleotide of claim 11, the hybridization comprising: Performed under conditions that form a specific hybridization complex with a target polynucleotide, wherein the target polynucleotide is a polynucleotide comprising a polynucleotide sequence of the polynucleotide of claim 11 or a fragment thereof, Said step;
(C) quantifying the yield of the hybridization complex;
(D) comparing the yield of hybridization complex in the treated biological sample with the yield of hybridization complex in the untreated biological sample;
A method for evaluating the toxicity of a test compound, wherein the difference in yield of the hybridization complex in the treated biological sample indicates the toxicity of the test compound.
(a)請求項10の抗体と前記ポリペプチドとの結合に好適な条件下で、前記生体サンプルを請求項10の抗体と結合させて、抗体/ポリペプチド複合体を形成するステップと、
(b)前記複合体を検出すステップとを含み、
前記複合体の存在が、前記生体サンプルにおける前記ポリヌクレオチドの存在と相関性を有することを特徴とする診断テスト。A diagnostic test for a condition or disease associated with the expression of RMEP in a biological sample comprising:
(A) binding the biological sample with the antibody of claim 10 under conditions suitable for binding of the antibody of claim 10 and the polypeptide to form an antibody / polypeptide complex;
(B) detecting the complex,
A diagnostic test characterized in that the presence of the complex is correlated with the presence of the polynucleotide in the biological sample.
(a)キメラ抗体、
(b)一本鎖抗体、
(c)Fab断片、
(d)F(ab’)2断片、または
(e)ヒト化抗体であることを特徴とする請求項10に記載の抗体。The antibody is
(A) a chimeric antibody,
(B) a single chain antibody,
(C) Fab fragment,
11. The antibody according to claim 10, which is (d) an F (ab ′) 2 fragment, or (e) a humanized antibody.
(a)抗体反応が起こる条件下で、SEQ ID NO:1−47からなる群から選択されたアミノ酸配列またはその免疫原性断片を有するポリペプチドで動物を免疫化するステップと、
(b)前記動物から抗体を単離するステップと、
(c)前記単離された抗体を前記ポリペプチドでスクリーニングして、SEQ ID NO:1−47からなる群から選択されたアミノ酸配列を有するポリペプチドに特異的に結合するポリクローナル抗体を同定するステップとを含むことを特徴とするポリクローナル抗体作製方法。A method for producing a polyclonal antibody having the specificity of the antibody of claim 10, comprising:
(A) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1-47 or an immunogenic fragment thereof under conditions in which an antibody response occurs;
(B) isolating an antibody from the animal;
(C) screening the isolated antibody with the polypeptide to identify a polyclonal antibody that specifically binds to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1-47 A method for producing a polyclonal antibody, comprising:
(a)抗体反応が起こる条件下で、SEQ ID NO:1−47からなる群から選択されたアミノ酸配列またはその免疫原性断片を有するポリペプチドで動物を免疫化するステップと、
(b)前記動物から抗体を産生する細胞を単離するステップと、
(c)前記抗体産生細胞を不死化細胞と融合し、モノクローナル抗体産生ハイブリドーマ細胞を形成するステップと、
(d)前記ハイブリドーマ細胞を培養するステップと、
(e)SEQ ID NO:1−47からなる群から選択されたアミノ酸配列を有するポリペプチドに特異的に結合する前記培養モノクローナル抗体から単離するステップとを含むことを特徴とするモノクローナル抗体作製方法。A method for producing a monoclonal antibody having the specificity of the antibody of claim 10, comprising:
(A) immunizing an animal with a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1-47 or an immunogenic fragment thereof under conditions in which an antibody response occurs;
(B) isolating cells producing antibodies from said animal;
(C) fusing the antibody-producing cells with immortalized cells to form monoclonal antibody-producing hybridoma cells;
(D) culturing the hybridoma cells;
(E) isolating from said cultured monoclonal antibody that specifically binds to a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NOs: 1-47. .
(a)請求項10の抗体と前記ポリペプチドとの特異的な結合が許容される条件下で、前記抗体を前記サンプルと共にインキュベートするステップと、
(b)特異的な結合を検出するステップとを含み、
前記特異的な結合が、前記サンプルにSEQ ID NO:1−47からなる群から選択されたアミノ酸配列を有するポリペプチドが存在することを示唆することを特徴とする方法。A method for detecting a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1-47 in a sample, comprising:
(A) incubating the antibody with the sample under conditions permitting specific binding of the antibody of claim 10 and the polypeptide;
(B) detecting specific binding,
The method wherein the specific binding suggests that there is a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1-47 in the sample.
(a)請求項10の抗体と前記ポリペプチドとの特異的結合が許容される条件下で、前記抗体を前記サンプルと共にインキュベートするステップと、
(b)前記サンプルから前記抗体を分離して、SEQ ID NO:1−47からなる群から選択されたアミノ酸配列を有する精製されたポリペプチドを得るステップとを含むことを特徴とする方法。A method of purifying from a sample a polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1-47,
(A) incubating the antibody with the sample under conditions permitting specific binding of the antibody of claim 10 and the polypeptide;
(B) separating the antibody from the sample to obtain a purified polypeptide having an amino acid sequence selected from the group consisting of SEQ ID NO: 1-47.
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US20018400P | 2000-04-28 | 2000-04-28 | |
US20209000P | 2000-05-04 | 2000-05-04 | |
US20187500P | 2000-05-04 | 2000-05-04 | |
US21023200P | 2000-06-06 | 2000-06-06 | |
US22055300P | 2000-07-25 | 2000-07-25 | |
PCT/US2001/013862 WO2001083524A2 (en) | 2000-04-28 | 2001-04-27 | Rna metabolism proteins |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2004511208A JP2004511208A (en) | 2004-04-15 |
JP2004511208A5 true JP2004511208A5 (en) | 2005-01-27 |
Family
ID=27539426
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2001580948A Pending JP2004511208A (en) | 2000-04-28 | 2001-04-27 | RNA metabolism protein |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1278843A2 (en) |
JP (1) | JP2004511208A (en) |
AU (1) | AU2001257427A1 (en) |
CA (1) | CA2407435A1 (en) |
WO (1) | WO2001083524A2 (en) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20020111307A1 (en) * | 2000-06-23 | 2002-08-15 | Glucksmann Maria Alexandra | 46508, a novel human peptidyl-tRNA hydrolase family member and uses thereof |
WO2002029057A2 (en) * | 2000-10-05 | 2002-04-11 | Millenium Pharmaceuticals, Inc. | 32144, a human fatty acid amide hydrolase and uses thereof |
US7074576B2 (en) * | 2001-11-23 | 2006-07-11 | Syn X Pharma, Inc. | Protein biopolymer markers indicative of alzheimer's disease |
US7179606B2 (en) * | 2001-11-23 | 2007-02-20 | Syn X Pharma, Inc. | IG heavy chain, IG kappa, IG lambda biopolymer markers predictive of Alzheimer's disease |
WO2013024467A2 (en) * | 2011-08-18 | 2013-02-21 | Ecole Polytechnique Federale De Lausanne (Epfl) | Mitochondrial ribosomal proteins as aging regulators |
US11161874B2 (en) * | 2016-08-19 | 2021-11-02 | Genoimmune Therapeutics Co., Ltd. | Tumor-specific polypeptide and use thereof |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5962226A (en) * | 1996-11-26 | 1999-10-05 | Incyte Pharmaceuticals, Inc. | Human RNA-binding protein |
AU3395900A (en) * | 1999-03-12 | 2000-10-04 | Human Genome Sciences, Inc. | Human lung cancer associated gene sequences and polypeptides |
JP2004507202A (en) * | 1999-03-31 | 2004-03-11 | キュラジェン コーポレイション | Nucleic acid containing an open reading frame encoding a polypeptide; "ORFX" |
WO2001087917A1 (en) * | 2000-05-18 | 2001-11-22 | Hyseq, Inc. | Novel nucleic acids and polypeptides |
-
2001
- 2001-04-27 EP EP01930939A patent/EP1278843A2/en not_active Withdrawn
- 2001-04-27 AU AU2001257427A patent/AU2001257427A1/en not_active Abandoned
- 2001-04-27 JP JP2001580948A patent/JP2004511208A/en active Pending
- 2001-04-27 CA CA002407435A patent/CA2407435A1/en not_active Abandoned
- 2001-04-27 WO PCT/US2001/013862 patent/WO2001083524A2/en not_active Application Discontinuation
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2479476A1 (en) | Compositions and methods for the treatment of tumor | |
JP2004513614A5 (en) | ||
JP2009039107A5 (en) | ||
JP2008086313A (en) | Therapeutic and diagnostic application of perlecan domain i splicing variant | |
US20110229889A1 (en) | DOPAMINERGIC NEURON PROLIFERATIVE PROGENITOR CELL MARKER Msx1/2 | |
US8604173B2 (en) | Dopaminergic neuron progenitor cell marker 187A5 | |
CN112920275B (en) | Binding proteins, reagents and kits that specifically bind to sST2 | |
KR20020008069A (en) | Diagnostic assay | |
JP2008523398A (en) | CD99 as a target / marker of insulin resistance | |
CA2501464A1 (en) | Lmna gene and its involvement in hutchinson-gilford progeria syndrome (hgps) and arteriosclerosis | |
JP2004515215A5 (en) | ||
JP2004511208A5 (en) | ||
US6503747B2 (en) | Serotype-specific probes for Listeria monocytogenes | |
JP2007145775A (en) | Method for detecting norovirus gi in high sensitivity | |
WO1997016461A1 (en) | Monoclonal antibody specific for prostaglandin d synthetase | |
CN116143909B (en) | anti-HIV-1P 24 antibody and preparation method and application thereof | |
JP2006518582A5 (en) | ||
KR101309485B1 (en) | Monoclonal antibody specific to Vibrio vulnificus RtxA1, hybridoma producing the monoclonal antibody and diagnostic kit comprising the monoclonal antibody | |
KR20140041435A (en) | Anti-il28b antibody and method for assaying il28b using same | |
CN112940130B (en) | Binding protein capable of specifically binding to MPO, use thereof, reagent, kit and method for detecting MPO | |
WO2012061281A1 (en) | Diagnostic assays and methods of use for detection of filarial infection | |
US11174310B2 (en) | Disulfide-type HMGB1-specific antibody, method for measuring disulfide-type HMGB1 and kit for said measurement, and measurement method capable of quantitating all of HMGB1 molecules including reduced HMGB1, disulfide-type HMGB1 and thrombin-cleavable HMGB1 and kit for said measurement | |
CN112979804B (en) | An isolated binding protein comprising a procalcitonin antigen-binding domain | |
CN115873103B (en) | Antibody for resisting novel coronavirus N protein, preparation method and application thereof | |
CN112920272B (en) | cTnI-resistant protein and method for detecting cTnI |